Drug Trial Radar · NCT05043766
Evaluation of Oral PF614 Relative to OxyContin (PF614-102)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Sep 8, 2021
Primary completion
Mar 21, 2022
Study completion Mar 21, 2022
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- Sep 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts of the study will be conducted in healthy adult subjects.
Conditions
- Healthy Volunteers
Interventions
PF614Drug
PF614 is an oxycodone prodrug
Naltrexone HydrochlorideDrug
Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
OxyContinDrug
Bioequivalence single-dose comparison to OxyContin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 30 days
- Pharmacokinetics AUC [Area Under the Curve]Time frame: Full PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Cmax [Maximum Plasma Concentration]Time frame: PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Tlag [Time to first measurable plasma concentration]Time frame: PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Tmax [Time to maximum plasma concentration]Time frame: PK sampling time points 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics AUC, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics CL/F [Clearance]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Cmax, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Tmax, Steady StateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics t1/2 [Half-life]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Vz/F [Volume of Distribution]Time frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics elimination rateTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Ctrough [Minimum Plasma Concentration before next dose]Time frame: Prior to dosing on Days 2, 3, and 4
- Pharmacokinetics Part B AUCTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Part B AUC 0-tTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Pharmacokinetics Part B CmaxTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
- Bioavailability and BioequivalenceTime frame: PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences-Early Development Services
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.